GlassScriptPhysician profile
Amy M Turner
NPI 1215261672
$13,388.81
in general payments reported to CMS, 2019-2025
54 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,414 · 2022: $2,508 · 2023: $2,849 · 2024: $2,038 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,405 · Education: $62.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,404.88 |
| Education | $62.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,553.26 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,444.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,088.64 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Abbvie INC. | $790.14 | 2021-2025 | |
| Medtronic, INC. | $718.51 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $717.22 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $691.72 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $650.71 | 2021-2025 | |
| Corcept Therapeutics | $484.47 | 2021-2025 | Korlym |
| Insulet Corporation | $442.98 | 2021-2025 | Omnipod |
| Amgen INC. | $432.18 | 2021-2025 | Tepezza, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.23 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $308.30 | 2021-2025 | Afrezza |
| Horizon Therapeutics Plc | $293.21 | 2021-2023 | Tepezza |
| Ibsa Pharma INC. | $252.41 | 2021-2025 | Licart, Tirosint, Flector |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.61 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $218.14 | 2023-2025 | Yorvipath |
| Genzyme Corporation | $213.86 | 2023 | |
| Cequr Corporation | $197.06 | 2022-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $196.12 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $167.10 | 2021 | |
| Kyowa Kirin, INC. | $166.23 | 2023-2024 | Crysvita |
| Zealand Pharma US, INC. | $127.11 | 2021-2022 | |
| Antares Pharma, INC. | $118.99 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Radius Health, INC. | $113.86 | 2021-2025 | Tymlos |
| Ultragenyx Pharmaceutical INC. | $109.51 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $108.87 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $93.58 | 2021-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $92.66 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $91.98 | 2023-2024 | Senza |
| Amneal Pharmaceuticals LLC | $89.73 | 2022-2025 | Unithroid |
| Tolmar, INC. | $81.10 | 2023-2025 | Jatenzo |
| Becton, Dickinson and Company | $79.03 | 2021 | |
| Merck Sharp & Dohme LLC | $62.88 | 2021 | |
| Averitas Pharma INC. | $61.88 | 2024 | Qutenza |
| Dexcom, INC. | $58.12 | 2022-2024 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $57.61 | 2025 | Rezdiffra |
| Shield Therapeutics INC | $37.53 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $36.29 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $35.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.81 | 2021-2024 | Fruzaqla |
| Renalytix Ai, INC. | $31.12 | 2022 | |
| Intuity Medical INC | $26.04 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Mycovia Pharmaceuticals, INC. | $24.73 | 2023 | Vivjoa |
| Beta Bionics, INC. | $23.90 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $23.29 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $23.07 | 2021 | |
| Opko Pharmaceuticals, LLC | $22.80 | 2024 | Rayaldee |
| Lifescan, INC. | $20.86 | 2021 | |
| Scynexis, INC. | $20.76 | 2022 | |
| Acerus Pharmaceuticals Corporation | $18.24 | 2022 | |
| Phadia US INC. | $16.59 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.73 | 2022 | |
| Currax Pharmaceuticals LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.